Tarsus Pharmaceuticals(NASDAQ) TARS

Tarsus Pharmaceuticals, Inc. NASDAQ:TARS makes eye drops that kill tiny eyelid mites. These parasites cause red and itchy eyes for many people. The company also develops pills to prevent tick-borne diseases.

What Tarsus Makes

• XDEMVY Eye Drops: First approved treatment targeting the mites that cause eyelid inflammation.
• TP-04 Gel: Investigational medicine designed to treat skin and eye redness from rosacea.
• TP-05 Oral Tablet: Experimental drug that kills ticks to stop Lyme disease transmission.
• IRX-101 Antiseptic: Eye solution meant to reduce pain after medical injections.
• Retinal Treatments: Late-stage oral pills being developed for inherited causes of blindness.

How the Company Grows

• Launched XDEMVY in Aug. 2023 to treat lid margin disease.
• Acquired iRenix Medical in July 2026 to expand into eye antiseptics.
• Entered an agreement to buy Alkeus Pharmaceuticals on July 31, 2026.
• Received a $15.0 million milestone payment for progress in China during 2026.
• Secured a $125.0 million private stock sale on Aug. 5, 2026.

A New Way to Kill Parasites

Tarsus uses a compound called lotilaner to paralyze parasites without harming human cells. This approach allows the company to treat specific infestations that previously lacked effective medical options.

The Financial Numbers

• Net product sales rose to $173.9 million in the second quarter of 2026, up more than 69% year over year.
• Total revenue reached $336.0 million for the six months ended June 30, 2026.
• Net loss was $18.6 million for the three months ended June 30, 2026.
• Cash and marketable securities totaled $449.7 million as of June 30, 2026.

Bottom Line

Tarsus has transitioned from a clinical-stage developer to a commercial pharmaceutical firm with a growing eye care and infectious disease pipeline. Its expansion into retinal health and tick-borne prophylaxis reflects a strategy of targeting high-need medical markets with novel chemical applications.